Acino International AG

Based in Zurich, Switzerland, and founded in 1836, Acino International AG (Acino), formerly known as Schweizerhall, operates as a pharmaceutical company that develops and manufactures novel drug delivery forms. In 1994, the firm got listed in the Swiss stock exchange (ticker symbol: ACIN), and in December 2013, Nordic Capital, Avista Capital Partners, and Ardian purchased Acino in a public-to-private deal for EUR 440. 24 million. The company acquired Copharm, in 2014, and PharmaStart in 2015.

As of November 2021, Acino International AG is being led by Steffen Saltofte, as its CEO, and employs more than 2,460 employees, and operates 5 manufacturing facilities across Switzerland, Ukraine, Estonia, and South Africa. The company develops and manufactures pharmaceuticals in novel drug delivery forms, intended for the treatment of infections, nervous system disorders, urology system disorders, and cardiovascular diseases, etc, and sells medicines under the brand name, Acino Switzerland, across the markets of Middle East, Africa, Ukraine/CIS including Russia, and Latin America. Additionally, Acino International AG provides out-licensing of its in-house developed generic products, to its client companies and other pharma businesses, and furthermore offers contract manufacturing services extending from drug development, manufacturing, to packaging and logistics. As of December 2020, Acino International AG generated more than EUR 480 million in sales.